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Abstract
The multiple banded antigen (MBA) is a predicted virulence factor of Ureaplasma species. Antigenic variation of the MBA is a
potential mechanism by which ureaplasmas avoid immune recognition and cause chronic infections of the upper genital
tract of pregnant women. We tested whether the MBA is involved in the pathogenesis of intra-amniotic infection and
chorioamnionitis by injecting virulent or avirulent-derived ureaplasma clones (expressing single MBA variants) into the
amniotic fluid of pregnant sheep. At 55 days of gestation pregnant ewes (n = 20) received intra-amniotic injections of
virulent-derived or avirulent-derived U. parvum serovar 6 strains (26104 CFU), or 10B medium (n = 5). Amniotic fluid was
collected every two weeks post-infection and fetal tissues were collected at the time of surgical delivery of the fetus (140
days of gestation). Whilst chronic colonisation was established in the amniotic fluid of animals infected with avirulent-
derived and virulent-derived ureaplasmas, the severity of chorioamnionitis and fetal inflammation was not different
between these groups (p.0.05). MBA size variants (32–170 kDa) were generated in vivo in amniotic fluid samples from both
the avirulent and virulent groups, whereas in vitro antibody selection experiments led to the emergence of MBA-negative
escape variants in both strains. Anti-ureaplasma IgG antibodies were detected in the maternal serum of animals from the
avirulent (40%) and virulent (55%) groups, and these antibodies correlated with increased IL-1b, IL-6 and IL-8 expression in
chorioamnion tissue (p,0.05). We demonstrate that ureaplasmas are capable of MBA phase variation in vitro; however,
ureaplasmas undergo MBA size variation in vivo, to potentially prevent eradication by the immune response. Size variation
of the MBA did not correlate with the severity of chorioamnionitis. Nonetheless, the correlation between a maternal
humoral response and the expression of chorioamnion cytokines is a novel finding. This host response may be important in
the pathogenesis of inflammation-mediated adverse pregnancy outcomes.
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Introduction
The two Ureaplasma species, which cause infections in humans
are Ureaplasma parvum (serovars 1, 3, 6 and 14) and Ureaplasma
urealyticum (serovars 2, 4, 5, 7–13) [1]. Phenotypically the
ureaplasmas are distinguished from the closely related Mycoplasma
species by their ability to hydrolyse urea to generate 95% of their
ATP [2,3]. The ureaplasmas are generally regarded as commen-
sals of the lower genital tract in both males and females and can be
isolated from the vagina or cervix in 40–80% of sexually active
females [4,5]. However, ureaplasma infection of the upper genital
tract during pregnancy is associated with adverse pregnancy
outcomes including preterm birth and chorioamnionitis [5,6].
Ureaplasmas are hypothesized to gain access to the upper
genital tract of pregnant women by various mechanisms including
(i) ascending invasive infection from the lower genital tract; (ii)
transplacental or haematogenous spread; or (iii) iatrogenic needle
contamination at the time of amniocentesis or chorionic villous
sampling [7]. Although ureaplasmas are the bacteria most
frequently isolated from infected amniotic fluid (AF) in pregnant
women [8–10], the pathogenic role of these microorganisms
during pregnancy is unclear, as ureaplasmas have also been
isolated from the AF of women with apparently normal pregnancy
outcomes after delivery at term [8,9,11]. These discrepancies
demonstrate that a causal relationship has not been established
between intra-amniotic ureaplasma infection and adverse preg-
nancy outcomes.
Initial serotyping studies of invasive ureaplasmas isolated from
CSF and blood cultures of neonates demonstrated that no one
serovar was more associated with disease, and that invasiveness
was not likely to be limited to one particular serotype [12]. Rather,
it was hypothesised that the virulence of individual ureaplasma
strains may be determined by antigenic variation and/or host
factors [5,12]. The multiple banded antigen (MBA) is a surface
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exposed lipoprotein, which can undergo size and phase variation in
vitro and in vivo [13–17]. The MBA gene (mba) consists of a 59
conserved region, which encodes a signal peptide and membrane
anchor and a 39 repetitive region, which consists of multiple tandem
repeat units [14]. The MBA is predicted to be a major ureaplasmal
virulence factor and is the predominant antigen recognised by sera
during infections in humans [18]. Recently, our group demonstrat-
ed that MBA size variation was associated with the severity of
histological chorioamnionitis in a pregnant sheep model of intra-
amniotic ureaplasma infection [17]. From this previous work, we
cultured a clonal U. parvum serovar 6 virulent-derived strain
(associated with severe histological chorioamnionitis) and a clonal
avirulent-derived strain (associated with no signs of histological
chorioamnionitis), which we aimed to characterize further in vivo.
Whilst it is evident that certain ureaplasma isolates are more
associated with severe disease than others, it is not known if the
invasive properties associated with these isolates are determined
primarily by bacterial factors (such as size/phase variation of the
MBA) or host factors (including the immune response). Using our
established sheep model of chronic intra-amniotic ureaplasma
infection, we tested whether clonal ureaplasma isolates with
defined MBA profiles (derived from virulent or avirulent parent
strains, associated with either severe, or no chorioamnionitis) are
intrinsically virulent or avirulent. For this study we defined
virulence as the extent of damage to the host during infection with
a pathogen, as defined by Brown et al. [19]. We hypothesized that
virulence is not likely to be associated with specific ureaplasma
isolates, but rather that the severity of disease may be determined
by the host immune response generated against intra-amniotic
ureaplasma infection. We predicted that interactions between
ureaplasmas and the host immune response may be mediated by
size/phase variation of the MBA and that variable expression of
the MBA would enable ureaplasmas to avoid eradication by host
immune factors. By measuring pregnancy/fetal outcomes, urea-
plasma colonization of fetal tissues, MBA in vivo expression profiles
and the host immune response we aimed to provide insight into
the role of the MBA during microbial invasion of the amniotic
cavity and the chorioamnion.
Materials and Methods
Ethics Statement
This study was carried out in accordance with the NHMRC
‘Australian code of practice for the care and use of animals for
scientific purposes’ and approved by the UWA Animal Ethics
Committee (Approval No. RA/3/100/619). Preterm lambs were
surgically delivered by Caesarean section. Ewes were pre-
medicated with an intra-venous injection of ketamine (10 mg/kg
bodyweight) and medetomidine (0.02 mg/kg) and a subdural
injection of 2% lignocaine (60 mg). The fetus was delivered and
then euthanized using sodium pentobarbitone, 100 mg/kg. The
ewe was killed by sodium pentobarbitone, 100 mg/kg.
Source of ureaplasma isolates
The U. parvum serovar 6 strains used for intra-amniotic injection
were expanded from single colony forming units (CFUs) derived
from ‘virulent’ and ‘avirulent’ ureaplasmas isolated from the AF of
pregnant sheep from our previous experiment [17]. The parent
strains (E24 and E22) were classified as virulent and avirulent
respectively, based on the severity of chorioamnionitis associated
with intra-amniotic infection and the number of MBA variants
detected within the AF at the time of preterm delivery. Infection
with isolate E24 was associated with severe chorioamnionitis
(resulting in fibrosis and tissue lesions) and a low number of AF
MBA size variants (n = 5); whereas infection with isolate E22 did
not result in histological chorioamnionitis and a greater number of
MBA size variants were detected within the AF (n = 14, data
presented in reference [17]). For this current experiment, to obtain
ureaplasmas expressing single MBA size variants derived from
single CFUs, E22 and E24 cultures were cloned and filtered three
times, as described previously [20]. Cloned ureaplasmas were
designated E22 5.8.1 (originating from the avirulent parent strain)
and E24 3.2.1 (originating from the virulent parent strain).
Animal model
At 55 days of gestation (d, term = 150 d) 25 pregnant Merino
ewes were randomized to receive ultrasound-guided intra-
amniotic injections (virulent-derived clone E24 3.2.1: n = 10;
avirulent-derived clone E22 5.8.1: n = 10; 10B medium control:
n = 5). Prior to the injection of ureaplasmas, AF was aspirated to
verify: (i) the injection site by electrolyte analysis (Rapidlab 865,
Bayer Diagnostics, Pymble, NSW); and (ii) to test that animals did
not have pre-existing intra-amniotic ureaplasma infections.
Ureaplasma isolates and 10B medium were prepared for injection
in 2 mL volumes, which consisted of 26104 CFU or 10B medium
diluted in PBS [21]. AF was sampled from each animal by
ultrasound-guided amniocentesis approximately every two weeks
(at 73, 87, 101, 115 and 126 days of gestation) post intra-amniotic
injection and was tested by culture and western blot.
Near-term fetuses were delivered surgically at 140 d [17,22] and
samples of AF, chorioamnion, cord, fetal lung and fetal CSF were
aseptically collected. Complete blood counts were performed on
umbilical arterial blood.
Ureaplasma culture
Ureaplasmas were cultured from AF, chorioamnion, cord, fetal
lung and fetal CSF specimens in 10B broth medium [17,20,22].
Ureaplasmas within specimens were quantified by standard drop
plate analysis, and are reported as the number of CFU/mL of
fluid, or CFU/gram of tissue.
mba PCR
To determine the size and number of mba variants within clonal
ureaplasma isolates E22 5.8.1 and E24 3.2.1, the downstream
repeat region of the mba was amplified by PCR, as described
previously [17].
MBA western blots
Ureaplasma MBA size variants were detected in un-cultured AF
specimens collected at 73 d, 87 d, 101 d, 115 d, 126 d and 140 d
by western blot. Western blots were performed directly on
centrifuged AF rather than ureaplasmas cultured from AF, as
culture can select for sub-populations of MBA variants, and
therefore results are not representative of the pool of size variants
originally present within the AF (data not shown). 10 mL of
thawed AF was centrifuged at 52506g for 20 minutes at 4uC. The
supernatant was discarded and the pellet then was resuspended in
100 mL of PBS. SDS-PAGE and western blots were performed
as described previously [17]. The primary antibody used for
detection of the MBA was rabbit polyclonal antisera raised against
U. parvum serovar 6 (courtesy of Emeritus Dr Patricia Quinn)
diluted 1/5000 in blocking solution (5% skim milk, 150 mM
NaCl, 50 mM Tris). Membranes were further probed with a goat
anti-rabbit IgG-HRP secondary antibody (Sigma Aldrich, Castle
Hill, NSW) diluted 1/5000; and MBA protein bands were
detected by 39, 39-diaminobenzidine tetrahydrochloride (DAB)
staining with cobalt chloride (Sigma). Proteins extracted from
The Role of the MBA in Intra-Amniotic Infection
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ureaplasma isolates E22 5.8.1 and E24 3.2.1 were included in each
western blot as positive controls.
Histopathology
Formalin-fixed paraffin-embedded tissues were cut into 5 mm
sections and stained with haematoxylin and eosin (H & E, all tissue
types) and Masson’s trichrome stain (chorioamnion samples only).
Sectioning and staining was performed by QML Vetnostics
(Murarrie, QLD). Inflammatory cell counts were performed on H
& E stained sections to determine the numbers of monocytes,
macrophages, lymphocytes, band neutrophils and polymorphonu-
clear neutrophils (PMNs) in 20 fields of view at 61000 total
magnification. Masson’s trichrome-stained chorioamnion sections
were graded using our previously described scoring system [22] to
determine the severity of histological chorioamnionitis. Histopath-
ological analysis of H & E and Masson’s trichrome stained tissues
was performed blinded to animal treatment groups.
RNA extraction and RT-PCR
Total RNA was extracted from 20 mg of freshly thawed
chorioamnion and fetal lung samples collected at 140 d using
the Qiagen RNeasy Mini Kit (Qiagen, Doncaster, VIC). The
quantity of eluted RNA was measured using the NanoDrop 1000
spectrophotometer (Thermo Fischer Scientific Australia Pty Ltd,
Scoresby, VIC) and 1.5 mg of cDNA was synthesised from RNA
template by RT-PCR using Invitrogen’s Super Script III First-
Strand Synthesis Supermix for q-PCR (Invitrogen, Mulgrave,
VIC). RT-PCR conditions consisted of: 25uC for 10 minutes,
50uC for 30 minutes, and 85uC for 5 minutes. cDNA samples
were then chilled on ice, and contaminating RNA was degraded
by the addition of RNase H followed by incubation at 37uC for
20 minutes. cDNA was stored at 220uC until use.
Quantitative Real time PCR
Quantitative real time PCR was performed on chorioamnion
and fetal lung cDNA samples to determine the expression of:
Toll-like receptor (TLR) 1, TLR2, TLR6, interleukin (IL)-1b, IL-
6, IL-8, IL-10 and tumor necrosis factor-a (TNF-a), relative to
the expression of GAPDH. Previously published PCR primers
[23–25] (Table 1) were used to amplify sheep-specific sequences.
PCR assays incorporated 16 Platinum SYBR Green qPCR
SuperMix-UDG (Invitrogen); either 0.4 mM of each primer
(GAPDH, TLR1, TLR2 and TLR6) or 0.5 mM of each primer
(IL-1b IL-6, IL-8, IL-10, TNF-a); 25 ng of cDNA and sterile
distilled H2O to a final volume of 20 mL. Real time PCR cycling
was performed in a Qiagen Rotor-Gene Q thermocycler (Qiagen,
Doncaster, VIC), and included initial incubation at 50uC for
10 minutes and an initial denaturation step at 95uC for
10 minutes. Cycling then consisted of 40 cycles of: denaturation
at 94uC for 15 seconds (GAPDH, TLR1, TLR2 and TLR6) or
20 seconds (IL-1b IL-6, IL-8, IL-10 and TNF-a); annealing at
52uC to 58uC (specific annealing temperatures for each primer
pair are shown in Table 1); and extension at 72uC for 20 seconds
(IL-1b IL-6, IL-8, IL-10 and TNF-a) or 40 seconds (GAPDH,
TLR1, TLR2 and TLR6). Cycle thresholds (CT) were calculated
using Rotor-Gene Q series software version 1.7 (Qiagen) and
PCR product specificity was confirmed by standard melt curve
analysis. Prior to the testing of chorioamnion and fetal lung
cDNA samples, the amplification efficiency of each of the primer
pairs was validated (data not shown), as per the protocol
published by Schmittgen and Livak [26]. All primer efficiencies
were found to be within +/210% of the efficiency of the
reference gene (GAPDH, 95% efficiency).
All chorioamnion and fetal lung samples were tested in triplicate
and mean CT values from animals infected with virulent-derived
Table 1. PCR primers used for the amplification of selected Toll-like receptor (TLR) and cytokine genes from chorioamnion and
fetal lung cDNA.
PRIMER SEQUENCE (59 to 39) ANNEALING TEMPERATURE SOURCE
GAPDH (F) GTCCGTTGTGGATCTGACCT 58uC Chang et al. 2009 [24]
GAPDH (R) TGCTGTAGCCGAATTCATTG 58uC Chang et al. 2009 [24]
TLR1 (F) TTGCACATCAGCAAGGTTTT 58uC Chang et al. 2009 [24]
TLR1 (R) CACTGTGGTGCTGACTGACA 58uC Chang et al. 2009 [24]
TLR2 (F) GGCTGTAATCAGCGTGTTCA 58uC Chang et al. 2009 [24]
TLR2 (R) GATCTCGTTGTCGGACAGGT 58uC Chang et al. 2009 [24]
TLR6 (F) TTTGTCCTCAGGAACCAAGC 58uC Chang et al. 2009 [24]
TLR6 (R) TCATATTCCAAAGAATTCCAGCTA 58uC Chang et al. 2009 [24]
IL-1b (F) CCTTGGGTATCAGGGACAA 57uC McNeilly et al. 2008 [23]
IL-1b (R) TGCGTATGGCTTTCTTTAGG 57uC McNeilly et al. 2008 [23]
IL-6 (F) TCCAGAACGAGTTTGAGG 52uC Egan et al. 1996 [25]
IL-6 (R) CATCCGAATAGCTCTCAG 52uC Egan et al. 1996 [25]
IL-8 (F) ATCAGTACAGAACTTCGA 55uC McNeilly et al. 2008 [23]
IL-8 (R) TCATGGATCTTGCTTCTC 55uC McNeilly et al. 2008 [23]
IL-10 (F) TGAAGGACCAACTGAACAGC 55uC Egan et al. 1996 [25]
IL-10 (R) TTCACGTGCTCCTTGATGTC 55uC Egan et al. 1996 [25]
TNF-a (F) GAATACCTGGACTATGCCGA 58uC McNeilly et al. 2008 [23]
TNF-a (R) CCTCACTTCCCTACATCCCT 58uC McNeilly et al. 2008 [23]
IL = interleukin, TNF = tumor necrosis factor, F = forward primer, R = reverse primer.
doi:10.1371/journal.pone.0029856.t001
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(E24 3.2.1) and avirulent-derived (E22 5.8.1) ureaplasmas were used
to calculate the expression of target genes relative to GAPDH and
normalised against the expression of target genes in non-infected
control animals. Relative expression was determined by the equation
published by Pfaffl [27], where the relative expression ratio
= (Efficiencytarget gene)
DCT(control – sample)/(Efficiencyreference gene)
DCT(control – sample). This method was selected as opposed to the
DDCT method of relative expression, as the equation presented by
Pfaffl [27] does not assume that PCR efficiencies are equal between
the reference and target genes.
Detection of anti-ureaplasma IgG antibodies
Western blots were performed to determine if anti-ureaplasma
IgG antibodies were present in maternal and/or fetal sera, as
indicators of a humoral immune response. Standardised protein
extracts of whole ureaplasma isolates E22 5.8.1 and E24 3.2.1
were loaded into the wells of 10% SDS-PAGE gels, electropho-
resed, transferred onto nitrocellulose membrane and blocked as
described above. Maternal or fetal serum (diluted 1/100 in
blocking solution) was used as the primary antibody, and
membranes were incubated with these sera overnight at 4uC.
Membranes were washed and then probed with secondary
antibody (anti-sheep IgG (whole molecule)-HRP, raised in donkey
(Sigma)) diluted 1/1000. The presence of protein bands (detected
by DAB staining with cobalt chloride (Sigma)) indicated binding of
antibodies within the serum to ureaplasmal proteins from either
the virulent-derived or avirulent-derived ureaplasma strain. All
samples were tested in duplicate.
Serial passage of virulent and avirulent-derived clonal
ureaplasmas
Serial passage experiments were performed by inoculating
26104 CFU/mL of ureaplasma strains E22 5.8.1 and E24 3.2.1
into 1.8 mL of 10B medium containing rabbit polyclonal U. parvum
serovar 6 antiserum (at a final dilution of 1/500). Inoculated
broths were incubated at 37uC aerobically until a colour change
was evident within the media (usually occurring between 12 and
18 hours). Ureaplasmas were then transferred into fresh 10B
medium (at a concentration of approximately 104 to 105 colour
changing units per mL) containing antibodies, and were again
incubated. Each ureaplasma isolate was serially passaged 20 times
in culture media containing antibodies. After each passage,
samples were collected for western blot. As a control, ureaplasma
isolates E22 5.8.1 and E24 3.2.1 were also serially transferred in
10B medium without antibodies 20 times.
Statistical analysis
Pregnancy outcomes, complete blood count data, inflammatory
cell counts and ureaplasma tissue colonization data were initially
analysed for homogeneity of variances by Levene’s test. Those
data for which homogeneity of variances were confirmed were
subsequently analysed by one-way analysis of variance (ANOVA)
with a Tukey post hoc test. If the assumption of homogeneity of
variance was violated, the Welch statistic was alternatively
reported. Fetal lung compliance, AF colonization and MBA size
variant data were analysed by a two-way repeated measures
ANOVA, and degrees of freedom were corrected using Green-
house-Geisser estimates if the assumption of sphericity was
violated. Independent t-tests were used to analyse humoral
immune response and qRT-PCR data. Data are presented as
mean 6 standard error of the mean (SEM) and statistical
significance was accepted at p,0.05.
Results
Pregnancy outcomes
Of the 25 pregnant ewes that received intra-amniotic injections,
fetuses were spontaneously aborted from three ewes (virulent
group n = 2; avirulent group n = 1) at approximately 82 d, 115 d
and 131 d (Table 2). One ewe (avirulent group) also delivered a
stillborn fetus at 131 d after preterm labor. Oligohydramnios was
observed at least once during the amniocentesis sampling period in
three animals from the avirulent group, in two animals from the
virulent group, but not in the control group. Meconium-stained
Table 2. Pregnancy outcomes and fetal measurements at the time of delivery (140 d).
VIRULENT GROUP AVIRULENT GROUP CONTROL GROUP P VALUE
Pregnancy outcomes
Abortion/stillborn fetus 2 (20%) 2 (20%) 0 (0%) 0.59
Oligohydramnios 2 (20%) 3 (30%) 0 (0%) 0.42
Meconium-stained amniotic fluid 4 (40%) 0 (0%) 0 (0%) 0.01
Gender (female : male) 5:3 5:3 3:2 0.10
Fetal birth weight (kg) 4.860.3 5.360.2 5.360.3 0.36
Fetal lung weight (g/kg body weight) 28.361.4 31.461.9 30.462.8 0.50
Lung volume (mL/kg) at 40 cm H2O pressure 36.264.0 42.161.7 37.763.6 0.06
Umbilical arterial cord blood gases
pH 7.260.03 7.2160.03 7.1960.05 0.09
pO2 (mmHg) 9.660.6 9.960.9 12.861.6 0.08
Umbilical arterial white blood cell counts
Total (6109/L) 4.260.9 3.960.5 3.660.6 0.87
Monocytes (6109/L) 0.360.1 0.160.04 0.260.1 0.54
Lymphocytes (6109/L) 2.260.3 2.060.2 2.160.4 0.86
Neutrophils (6109/L) 1.260.6 0.960.1 0.860.2 0.75
doi:10.1371/journal.pone.0029856.t002
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AF was present in four animals from the virulent group at least
once throughout the sampling period; however, meconium was
not present in AF from animals from the avirulent group or the
media control group. Pregnancy loss and oligohydramnios
occurred independently of the animal group (p = 0.59 and
p = 0.42 respectively). The presence of meconium-stained AF
was significantly increased in the virulent group compared to the
avirulent group and the media control group (p = 0.01).
Fetal birth weight, fetal lung weight and umbilical arterial cord
blood pH, pO2 and white blood cell counts were not different
between animal groups (p.0.05, Table 2). Chronic intra-amniotic
infection with the avirulent-derived (E22 5.8.1) ureaplasma strain
tended to increase lung compliance in near-term fetuses (as
determined by a deflation pressure-volume curve, Table 2), when
compared to the virulent and control groups. However this
observed increase was not statistically significant (p = 0.06).
Ureaplasmas can chronically colonise the amniotic fluid
AF collected from all ewes prior to intra-amniotic injection at
55 d tested negative for ureaplasmas. Following intra-amniotic
injection, the AF from all ewes inoculated with ureaplasmas (either
isolate E22 5.8.1 or isolate E24 3.2.1) tested positive for
ureaplasmas at all time points (Figure 1A). The peak of infection
occurred at 87 d for the avirulent group (7.263.16107 CFU/mL)
and at 101 d for the virulent group (5.362.16107 CFU/mL).
Ureaplasma AF colonization at 87 d was significantly increased in
the avirulent group compared to the virulent group (p = 0.002);
however, there were no differences in colonization at any other
time points between these groups. High numbers of ureaplasmas
were recovered from the AF in both the avirulent
(9.666.46106 CFU/mL) and virulent (1.660.86107 CFU/mL)
groups at 140 d. For each experimental animal group differences
in the AF ureaplasma CFU/mL were observed: (i) between 87 d
and 101 d for the virulent group only (p = 0.04); and (ii) between
87 d and 126 d for both the avirulent and virulent groups
(p = 0.02). Ureaplasmas were not detected in the AF of non-
infected controls.
All animals from the avirulent and virulent groups tested
culture-positive for ureaplasmas within the chorioamnion at 140 d
(Figure 1B). Ureaplasmas were cultured from the cords of 4 out of
8 (50%) animals from both the virulent and avirulent groups; and
from the fetal lungs of 5 out of 8 (62.5%) lambs from the virulent
group and 6 out of 8 (75%) lambs from the avirulent group. No
ureaplasmas were detected in fetal CSF specimens (as determined
by both culture and PCR, data not shown), or from any tissue
specimens from non-infected control animals. Ureaplasma colo-
nization in chorioamnion (p = 0.38), cord (p = 0.66) and fetal lung
(p = 0.49) tissues were not different between treatment groups.
Intra-amniotic ureaplasma infection is associated with
fetal inflammation
Inflammatory cell counts within chorioamnion tissue were
higher in animals injected with virulent-derived and avirulent-
derived ureaplasmas when compared to controls. However,
inflammatory cell counts were not different between the virulent
and avirulent groups for any of the cell types (p.0.05, Figure 2A).
The number of macrophages and PMNs within chorioamnion
sections were significantly increased in both the virulent and
avirulent groups when compared to controls (p = 0.02 and p = 0.03
respectively). Grading of chorioamnion sections demonstrated that
animals in the 10B medium control group had no evidence of
histological chorioamnionitis, but moderate to severe histological
chorioamnionitis was evident in both the avirulent and virulent
groups (p = 0.001, Figure 2B). Representative chorioamnion sec-
tions stained with H & E and Masson’s trichrome stain (Figure 2C)
demonstrated the various grades of histological chorioamnionitis.
Non-infected chorioamnion tissues were characterized by mini-
mal/no inflammatory cell influx and a well-defined structure
consisting of a thin layer of fibroblasts bordering intact epithelial
cells. In contrast, histological chorioamnionitis was associated with
increased localized inflammatory cell influx, fibrosis and/or scar
tissue (as indicated by thickening of fibroblast layers and lesion
formation) and an irregular epithelial layer. Umbilical cord and
fetal lung inflammatory cell counts were not different between
groups (Figures 2D and 2E, p.0.05).
MBA size variation occurs in vivo
Ureaplasma MBA size variants were detected by western blot in
AF specimens collected at 73 d, 87 d, 101 d, 115 d, 126 d and
140 d. The avirulent-derived and virulent-derived ureaplasma
clones used for intra-amniotic injection each expressed a single mba
size variant as determined by PCR (Figure 3A); however, these
appeared as double bands in western blots (Figure 3B). MBA
bands of approximately 45 kDa and 50 kDa (E22 5.8.1); and
50 kDa and 55 kDa (E24 3.2.1) were detected in the avirulent-
derived and virulent-derived strains respectively. Antigenic size
variation was detected within all tested AF samples from the
avirulent group (Figure 3C) and the virulent group (Figure 3D),
and MBA bands ranged in size from 32 kDa to 170 kDa. In the
avirulent group all detected MBA proteins were equal in size to, or
had an increased molecular weight when compared to the E22
5.8.1 inoculum. In the virulent group, the range of MBA size
variants was greater, as MBA bands of lower, equal and higher
molecular weight were detected.
From these AF specimens, the total numbers of MBA size
variants detected ranged from one to eight. The average number
of AF MBA size variants in the avirulent group increased over the
first three time points and reached a maximum of four variants at
101 d (Figure 3E). Following this, the number of MBA size
variants decreased over the last three time points. Within the
virulent group the average number of MBA size variants within
the AF initially increased at 87 d, peaked at 126 d, and then
decreased at 140 d. The number of MBA size variants detected
within AF specimens was not different between animal groups at
any of the tested time points (p = 0.87), nor were there differences
in the number of MBA size variants within the two groups for the
entire gestation (p = 0.32).
Intra-amniotic ureaplasma infection stimulates a
maternal and fetal humoral response
Anti-ureaplasma IgG antibodies were detected in the maternal
serum of four ewes from the avirulent group and five ewes from
the virulent group (Figure 4A). In the avirulent group, the
maternal antibodies from each positive ewe reacted with
ureaplasmal proteins (ranging in size from approximately
45 kDa to 87 kDa), which were different in size to the MBA
variants detected in AF specimens (as determined by molecular
weight comparison). Within this avirulent group, the maternal
serum of one ewe (animal 2) reacted with two ureaplasmal
proteins, whilst the sera from the other three animals reacted with
only one protein. Positive sera were also probed against protein
extracts from MBA-negative avirulent-derived ureaplasma clones
(generated from serial in vitro transfer experiments). Comparison
of protein bands recognised by maternal serum when probed
against whole ureaplasma protein extract or MBA-negative urea-
plasma protein extract (Table 3) demonstrated that two (out of
four) serum samples from the avirulent group detected a protein of
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approximately 45 kDa, which was expressed in both whole
ureaplasma and MBA-negative ureaplasma preparations.
In the virulent group, one ewe (animal 42) produced antibodies
only against a 50 kDa protein, whereas the other four ewes
produced antibodies against more than one ureaplasmal protein
(ranging in size from approximately 45 kDa to 80 kDa), including
(but not limited to) MBA size variants that were detected within
the AF of each animal. When positive sera from the virulent group
were probed against MBA-negative virulent-derived ureaplasma
protein extracts, three (out of five) serum samples also detected a
protein of approximately 45 kDa (Table 3).
Maternal serum collected from non-infected controls did not
react with ureaplasmal proteins and 10B medium, demonstrating
that antibodies were not generated against ureaplasmas or 10B
Figure 1. Ureaplasma colonization of amniotic fluid and fetal tissues. (A) Chronic infection of the amniotic fluid was observed in all ewes
experimentally infected with ureaplasmas from the time of inoculation (55 d) until fetuses were delivered at 140 d. Amniotic fluid ureaplasma
colonization was significantly increased in the avirulent group when compared to the virulent group at 87 d (p,0.05, denoted by #). Statistically
significant differences in amniotic fluid ureaplasma colonization within animal groups occurred between 87 d and 101 d; and 87 d and 126 d
(p,0.05). (B) Ureaplasmas were isolated from the chorioamnion, cord and fetal lung; however, recovered ureaplasma CFU/g was not different
between animal groups for the tested tissue types. * = statistically significant difference between time points in the virulent group only;
** = statistically significant difference between time points in both groups. AF = amniotic fluid; CFU= colony forming units; d = days of gestation. Data
are presented as mean 6 SEM.
doi:10.1371/journal.pone.0029856.g001
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medium components. The number of ewes which generated anti-
ureaplasma IgG antibodies was not different between the avirulent
and virulent groups (p = 0.35).
Anti-ureaplasma IgG was present within the fetal serum of one
fetus delivered from the avirulent group, and one fetus delivered
from the virulent group (Figure 4B). Fetal serum from both
positive fetuses reacted with only one ureaplasmal protein (animal
48, avirulent group: 60 kDa; and animal 83, virulent group:
80 kDa), both of which were not detected within the pool of MBA
size variants from the corresponding AF sample. Interestingly,
anti-ureaplasma IgG antibodies were produced in both the
maternal and fetal serum of animal 83; however, these sera
reacted with different ureaplasmal proteins (maternal serum:
approximately 45 kDa and 55 kDa; fetal serum: approximately
80 kDa).
Relative expression of ovine Toll-like receptors and
cytokines
Within chorioamnion tissue there were no statistically signifi-
cant increases or decreases in the expression of ovine Toll-like
receptors or cytokines between the avirulent and virulent groups
(Table 4). The expression of IL-1b, IL-6 and IL-8 tended to be up-
regulated in both the avirulent and virulent groups, relative to the
expression of GAPDH, although high levels of intra-animal
variation were observed, suggesting significant variability in the
host immune response. Within both ureaplasma-infected groups,
the relative expression levels of TLR1, TLR2 and TLR6 were
similar to expression levels in media control animals, whereas the
expression of TNF-a and IL-10 were slightly down-regulated
(albeit not statistically significant).
Similarly, within fetal lung tissue, high levels of intra-animal
variation were observed and there were no statistically significant
differences in the expression of Toll-like receptors or cytokines
between the avirulent and virulent groups (Table 4). Within the
avirulent group, the expression of IL-1b, IL-6 and IL-8 tended to
be down-regulated relative to GAPDH, whereas in the virulent
group some animals demonstrated up-regulation of TNF-a and
IL-10.
Interestingly, when these gene expression data were grouped
based on the presence of anti-ureaplasma IgG antibodies within
maternal serum (as opposed to treatment group) significant
differences were found. Specifically, the relative expression of
IL-1b, IL-6 and IL-8 within the chorioamnion was significantly
increased in animals which tested positive for anti-ureaplasma IgG
antibodies, when compared to those animals which tested negative
for the presence of these antibodies (IL-1b: p = 0.04; IL-6:
p = 0.02; IL-8: p = 0.04, Figure 5A). Furthermore, the relative
expression of TNF-a (p = 0.02) and IL-10 (p = 0.04) within
chorioamnion tissue was significantly decreased in IgG negative
animals, when compared to those animals which were positive for
anti-ureaplasma IgG antibodies (Figure 5B). The relative expres-
sion of TLR1, TLR2 and TLR6 also tended to be decreased in
IgG negative animals, when compared to IgG positive animals;
however, these data were not statistically significant (p = 0.20,
p = 0.08, p = 0.16 respectively, Figure 5C).
Serial passage of virulent and avirulent ureaplasmas
Serial passage of avirulent-derived E22 5.8.1 and virulent-derived
E24 3.2.1 ureaplasma strains in 10B medium without the presence of
anti-ureaplasma polyclonal rabbit sera did not lead to the emergence
of MBA escape variants or MBA size variants after 20 passages
(Figure 6). Conversely, when these strains were serially transferred in
10B medium containing rabbit anti-ureaplasma antibodies, MBA
escape variants were generated in both the avirulent-derived and
virulent-derived ureaplasma isolates (Figure 6). MBA-negative
ureaplasmas were generated after three serial transfers for isolate
E22 5.8.1, and after four serial transfers for isolate E24 3.2.1. MBA
size variation was not observed in any of these isolates.
Discussion
The pathogenic role of Ureaplasma spp. in adverse pregnancy
outcomes is controversial. The isolation of these microorganisms
from the upper genital tract of pregnant women who deliver at
term with no evidence of chorioamnionitis [8,9,11] suggests that a
causal relationship between intra-amniotic ureaplasma infection
and adverse pregnancy outcomes does not always exist. However,
advances in our understanding of the complexities of disease
pathogenesis have changed how we define microbial pathogens
and highlighted the importance of host-pathogen interactions in
predicting disease [28]. In this study, we investigated the role of
the MBA from virulent-derived and avirulent-derived ureaplasma
strains in a fetal sheep model of chronic intra-amniotic infection.
Our data suggest that ureaplasmas are not intrinsically virulent/
avirulent, as size variation of the MBA did not directly contribute
to fetal inflammation and chorioamnionitis. However, variation of
this surface-exposed antigen may prevent the eradication of
ureaplasmas by the host immune response. For the first time, we
have demonstrated a significant association between the up-
regulation of chorioamnion pro-inflammatory cytokines and the
presence of maternal serum anti-ureaplasma antibodies. We
predict that a strong host immune response may be an important
determinant in distinguishing asymptomatic intra-amniotic urea-
plasma infections from those resulting in adverse outcome.
Our data demonstrate that the incidences of fetal abortion and
oligohydramnios were not different between animals that received
intra-amniotic injections of virulent-derived ureaplasmas, aviru-
lent-derived ureaplasmas or 10B medium. Lung compliance
appeared to be increased in the avirulent group when compared
to the virulent and control groups; however, the number of
animals studied was too few to demonstrate statistical significance.
Previous data published by our group showed that long term intra-
amniotic ureaplasma infection induced fetal lung compliance in
preterm lambs (125 d) when compared to controls [29,30].
However, fetuses in the current experiment were delivered at
140 d (near-term), at which time fetal lungs are in the late
Figure 2. Fetal inflammation induced by intra-amniotic ureaplasma infection. Inflammatory cell infiltrates within chorioamnion tissue (A)
and the severity of histological chorioamnionitis (B) were increased in animals from the virulent and avirulent groups when compared to the control
group. Representative chorioamnion sections ((C) stained with haematoxylin and eosin (top row) or Masson’s trichrome stain (bottom row),
photographed at6200 total magnification) demonstrate the 4 stages of histological chorioamnionitis. From left to right: Grade 1 (uninfected control),
minimal inflammatory cell infiltrate and no tissue fibrosis, necrosis or abscesses; Grade 2, mild inflammatory cell infiltrate and mild tissue fibrosis,
necrosis or abscesses; Grade 3, heavy inflammatory cell infiltrate and moderate tissue fibrosis, necrosis or abscesses; Grade 4, heavy inflammatory cell
infiltrate and sever fibrosis, necrosis or abscesses. Stars on haematoxylin and eosin stained sections indicate localized inflammatory cell influx. Arrows
on Masson’s trichrome stained sections represent tissue fibrosis and disruption of normal tissue morphology. Size bars represent 50 mm.
Inflammatory cell infiltrates within cord tissue (D) and fetal lung tissue (E) were not statistically different between treatment groups. Data are
presented as mean + SEM. * p,0.05 when compared to the control group.
doi:10.1371/journal.pone.0029856.g002
The Role of the MBA in Intra-Amniotic Infection
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29856
The Role of the MBA in Intra-Amniotic Infection
PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e29856
saccular/early alveolar developmental phase [31] and are mature.
We observed a significant increase in the presence of meconium-
stained AF in the virulent group compared to both the avirulent
and control groups. Meconium-stained AF is reported to be a sign
of fetal stress and was associated previously with increased
incidences of intra-amniotic infection, chorioamnionitis and
intraventricular haemorrhage [32–36]. However, in our experi-
ment fetal outcomes were not different between animals with/
without meconium-stained AF, suggesting that the presence of
meconium within the AF may be an indirect indicator of infection
and/or fetal distress in some animals.
To the best of our knowledge, this is the first study to
demonstrate the progress of chronic intra-amniotic ureaplasma
infections over time. Remarkably, after 85 days of in utero infection,
ureaplasma colonization within the AF remained elevated
throughout gestation, as determined by amniocentesis sampling
at two weekly intervals. Even at 140 d, the AF ureaplasma CFU/
mL in both the avirulent and virulent animal groups was still two-
to-three logs higher than the original inoculum dose of
26104 CFU, demonstrating that AF is an excellent growth
medium for these microorganisms. It is well documented that
AF has bacteriostatic/bacteriocidal activity against numerous
bacteria such as Listeria monocytogenes, Escherichia coli, Staphylococcus
aureus and group B streptococci [37–39] due to various
components within the AF including zinc and phosphate
[40,41]. Therefore, the ability of the ureaplasmas to thrive within
the AF suggests that this may be a niche environment for these
microorganisms.
Figure 3. Size variation of the MBA was observed in amniotic fluid samples. PCR of the repeat region of the mba from ureaplasma isolates
E22 5.8.1 and E24 3.2.1 produced single amplicons prior to injection into pregnant sheep (A), indicating that these clonal isolates contained only one
mba size variant; however, western blots of the same isolates (B) demonstrated that the MBA appears as a double band. MBA size variants were
detected in vivo within the amniotic fluid of animals from the avirulent group (C) and the virulent group (D) by western blot. Each western blot
demonstrates the ureaplasma MBA size variants generated at 73, 87, 101, 115, 126 and 140 days of gestation in each animal. Note: samples were not
collected at some time points for certain animals due to oligohydramnios or other complicating factors. Protein preparations from the avirulent-
derived (E22 5.8.1) and virulent-derived (E24 3.2.1) ureaplasma clones used for intra-amniotic injection were included in each western blot (in the last
lane) as a positive control and for size comparison. M=DNA molecular weight marker VIII (Roche, Castle Hill, New South Wales) or protein marker
(BioRad, Gladesville, New South Wales). The average number of MBA size variants generated over time (E) was not different between animal groups.
doi:10.1371/journal.pone.0029856.g003
Figure 4. Demonstration of maternal and fetal anti-ureaplasma humoral responses. Anti-ureaplasma IgG antibodies were detected in the
maternal serum (A) and the fetal serum (B) of animals in both the avirulent and virulent groups. Antibodies in serum samples reacted with $1
ureaplasmal protein, over a wide molecular weight range (approximately 45 kDa to 80 kDa). Numbers above western blots indicate the animal
number from which the serum was obtained. M=protein marker (BioRad).
doi:10.1371/journal.pone.0029856.g004
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Our results indicate that ureaplasma colonization of the AF was
not affected by treatment group, as there were no differences in
CFU/mL (except at 87 d) between the avirulent and virulent
animal groups. Previously, we demonstrated that ureaplasma
colonization of the AF and fetal tissues occurred independently of
the serovar as well as the dose (high dose or low dose) used for
intra-amniotic injection [17]. We predict that a major regulator of
ureaplasmal growth within the AF may be pH, as ureaplasmas
require a pH of 6.0 for optimal growth [42] and the pH of ovine
AF ranges from 8.4 (at 70 d) to 7.4 (at 145 d) [43]. Similarly in
humans, the pH of AF from third trimester pregnancies is usually
7.160.08 [44], which may have a limiting effect on ureaplasmal
growth. Long-term colonization of the AF may be facilitated by
biofilm formation at the chorioamnion-AF interface, or within
‘amniotic fluid sludge’ (as reported by Romero et al. [45]). Garcia-
Castillo et al. [46] demonstrated that 82% of ureaplasmas isolated
from urine specimens collected from males diagnosed with
urethritis, chronic prostatitis or healthy individuals formed
biofilms in vitro. We also have preliminary data to suggest that
ureaplasmas isolated from the chorioamnion of experimentally-
infected sheep are capable of forming biofilms (Dando et al. 2010,
unpublished), indicating that this may be an important survival
mechanism for these microorganisms in vivo.
We did not observe differences in the severity of histological
chorioamnionitis between animals infected with the avirulent-
derived ureaplasma clone or the virulent-derived ureaplasma
clone. Both ureaplasma-infected groups had moderate to severe
chorioamnionitis, as determined by tissue scoring and inflamma-
tory cell counts. This is in contrast with our previous findings, in
which infection with the parent strains of avirulent (E22 5.8.1) and
virulent (E24 3.2.1) clones resulted in either no histological
evidence of chorioamnionitis, or severe chorioamnionitis respec-
tively [17]. We hypothesise that these differences may be
attributed to the elaboration of different MBA size variants in
utero between these two studies. In this experiment, both the
avirulent-derived and virulent-derived ureaplasma clones pro-
duced low numbers of MBA variants in vivo (average = 4.2 and 4.6
size variants respectively). Whereas previously, intra-amniotic
infection with a clinical ureaplasma isolate elaborated the avirulent
parent strain (associated with 14 MBA variants) and the virulent
parent strain (associated with 5 MBA variants). Despite differences
in the numbers of MBA size variants generated between these two
studies, the present data do confirm our previous observation that
low numbers of MBA size variants (#5) are associated with severe
histological chorioamnionitis.
Table 3. Comparison of the protein bands detected by anti-ureaplasma IgG antibodies in maternal serum when probed against
whole ureaplasma protein extract or MBA-negative ureaplasma protein extract.
PROTEIN BANDS RECOGNISED BY MATERNAL SERUM WHEN PROBED AGAINST:
ANIMAL # TREATMENT GROUP Whole ureaplasma protein extract MBA-negative ureaplasma protein extract
2 Avirulent 45 kDa, 87 kDa 45 kDa
29 Avirulent 80 kDa N/A
91 Avirulent 45 kDa 45 kDa
102 Avirulent 70 kDa N/A
42 Virulent 50 kDa 45 kDa
66 Virulent 55 kDa, 62 kDa, 87 kDa N/A
83 Virulent 45 kDa, 50 kDa 45 kDa
85 Virulent 45 kDa, 50 kDa, 55 kDa, 60 kDa N/A
96 Virulent 50 kDa, 55 kDa, 60 kDa 45 kDa
Those proteins indicated in bold were detected in western blots using both whole ureaplasma and MBA negative ureaplasma protein extracts. kDa = kilodaltons.
doi:10.1371/journal.pone.0029856.t003
Table 4. The relative expression of ovine Toll-like receptors and cytokines in chorioamnion and fetal lung tissue, relative to
GAPDH.
CHORIOAMNION FETAL LUNG
AVIRULENT GROUP VIRULENT GROUP P VALUE AVIRULENT GROUP VIRULENT GROUP P VALUE
TLR1 22.063.1 22.761.9 0.9 0.260.7 12.3610.8 0.3
TLR2 23.162.9 23.162.9 0.9 22.760.4 12.3614.6 0.3
TLR6 23.162.6 22.861.7 0.9 20.560.5 18.3617.4 0.3
IL-1b 5.462.9 48.2645.5 0.4 213.263.7 29.2611.9 0.7
TNF-a 27.464.9 24.063.3 0.6 20.760.7 81.3681.1 0.4
IL-6 47.5644.1 71.8639.7 0.7 230.9612.8 27.669.3 0.2
IL-8 87.3671.4 98.6681.4 0.9 238.3611.6 232.16 2.2 0.8
IL-10 25.864.3 28.565.9 0.7 21.860.7 230.66229.5 0.4
Data are presented as mean 6 SEM. TLR = Toll like receptor, IL = interleukin, TNF = tumor necrosis factor.
doi:10.1371/journal.pone.0029856.t004
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At the present time, we do not know the mechanisms that
drive MBA size variation in vivo, and are unable to explain the
differences in the number of MBA variants produced by the clonal
strains in comparison to the parent strains. However, an important
distinction between these two studies is that the inoculum strain
used for the previous experiment [17] was a non-clonal clinical
ureaplasma isolate, which may have comprised a mixture of MBA
subtypes. In contrast, the inocula used for the current experiment
were clonal strains, each expressing a single mba variant. Our data
demonstrate that clonal ureaplasma strains, unlike non-clonal
mixtures, may have a limited ability to generate MBA size variants
in vivo. Furthermore, clonal selection based on MBA antigenic
variation may have also selected for clones with altered expression
of other proposed ureaplasmal virulence factors, which include
urease, and phospholipase A and C [3]. Therefore, experiments to
characterize the expression of these additional virulence factors
throughout gestation may elucidate differences between clonally-
derived ureaplasma strains.
Antigenic variation, as defined by Deitsch et al. [47], refers to
the capacity of a microorganism to alter the proteins exposed to
the host immune system, such that the host is confronted with a
continually changing antigenic population that is difficult to
eliminate. Antigenic variation can refer to either phase variation
(on/off switching) or expression of alternate forms of an antigen
(such as size variation). Perhaps the best characterised examples of
antigenic variation are flagella phase variation in Salmonella spp.
[48] and Opa phase variation in Neisseria spp. [49]. However,
high frequency antigenic variation is also prominent in numerous
Mycoplasma spp. To date, the mechanisms of antigenic variation
described in mycoplasmas include: (i) slipped strand mispairing
and/or nucleotide insertions/deletions in simple sequence repeats;
and (ii) DNA rearrangements via site specific recombination and
promoter inversions [50]. Zimmerman et al. [16] demonstrated
that the MBA of U. parvum underwent alternate phase variation
with an adjacent gene, UU376. By in vitro selection using antibody
pressure, it was demonstrated that alternate expression of the
MBA/UU376 was associated with a DNA inversion event in
which the 59 conserved region of the mba and its putative promoter
were opposed to either the 39 repeat region of the mba or UU376.
Furthermore, phase variation of MBA N-terminal paralogs
(UU171 and UU172) was recently described in both U. parvum
and U. urealyticum [51]. Similarly to the alternate expression of
MBA/UU376, phase variation of UU171/UU172 is predicted to
occur via DNA inversion and rearrangement of potential
promoter sequences.
Whilst Zimmerman et al. [16] demonstrated that in vitro
antibody selection led to the emergence of MBA-negative escape
variants (via phase variation), our in vivo data demonstrated size
Figure 5. Pro-inflammatory cytokines were up-regulated in animals which produced ureaplasma-specific ureaplasma antibodies.
The relative expression of IL-1b, IL-6 and IL-8 within the chorioamnion was significantly increased in ewes that tested positive for anti-ureaplasma IgG
antibodies (IgG positive) within serum samples, when compared to animals in which these antibodies were not generated (IgG negative) (A).
Conversely, the relative expression of TNF-a and IL-10 (B); and TLR1, TLR2 and TLR6 (C) within the chorioamnion were decreased in IgG negative
animals when compared to IgG positive animals. Data are presented as mean fold change 6 SEM. * p,0.05. Expression of genes is determined
relative to the expression of GAPDH after normalisation against 10B medium control animals.
doi:10.1371/journal.pone.0029856.g005
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variability of the MBA after injection of clonal ureaplasmas
expressing a single mba variant. PCR of the repeat region of the
mba confirmed that isolates E22 5.8.1 and E24 3.2.1 each had one
mba size variant prior to intra-amniotic injection; however, the
MBA appeared as a double band in western blots. These findings
are similar to those reported by Zheng et al. [14], who suggested
that MBA doublets may be due to inefficient signal peptide
cleavage. However, it is also possible that this may be a result of
post-translational modification, such as glycosylation, but this
remains to be confirmed.
We have previously reported that ureaplasmas isolated from the
AF of pregnant sheep undergo MBA size variation [17]. As yet,
MBA-negative ureaplasmas have not been isolated from patients
or generated in vivo, therefore it is possible that phase variation of
the MBA is induced only by strong selection using antibodies
directed against the repetitive region of the MBA. To select for
MBA-negative escape variants, Zimmerman et al. [16] incubated
low numbers of clonal ureaplasmas with hyperimmune antisera
diluted 1/100. It is highly unlikely that these conditions would be
mimicked in vivo, which is perhaps why we have not observed
MBA phase variation in our sheep model. To determine whether
isolates E22 5.8.1 and E24 3.2.1 were capable of MBA phase
variation, we applied antibody pressure to these clonal ureaplas-
mas in vitro and found that MBA-negative variants were elaborated
after either three or four serial transfers. Similarly, we were only
able to achieve this using a high concentration of rabbit antisera,
which further suggests that MBA phase variation may only be
inducible in vitro using concentrated antibodies.
A primary function of antigenic variation is to evade the
adaptive immune response and to a lesser extent, the innate
immune response [47]. Our data demonstrated that MBA size
variants were generated in all animals, not just those in which anti-
ureaplasma IgG antibodies were detected. This suggests that MBA
size variation was not driven by the development of a host
humoral response, nor did it prevent recognition by host pattern
recognition receptors. However, continual size variation of the
MBA may prevent the eradication of ureaplasmas due to changes
to epitopes within the repeat region of the protein. Because IgG is
unable to cross the placenta in sheep, the ureaplasma-specific
antibodies detected in maternal sera were most likely generated in
response to ureaplasma invasion of maternal tissues, such as the
decidua. As expected, the sheep anti-ureaplasma IgG antibodies
were predominantly reactive against the MBA, however a 45 kDa
protein expressed by MBA-negative ureaplasma clones was also
found to be immunogenic. Previous studies have demonstrated
that the presence of serum antibodies against ureaplasmas was
more associated with preterm birth, low birth weight, stillbirth,
neonatal respiratory disease and fetal death when compared to
patients without anti-ureaplasma antibodies [52,53]. Quinn [52]
reported that a fetal antibody response to U. urealyticum occurred in
77.3% of stillbirths, 58.3% of respiratory disease cases, 69.3% of
neonatal deaths, 80.4% of term neonates with complications, but
only in 6.5% of healthy, term neonates (p#0.001). Additionally,
Horowitz et al. [53] reported that the rates of preterm birth and
fetal death were significantly higher in women with antibodies
against U. urealyticum compared to those without these antibodies
(90% vs. 43% (p = 0.006); and 85% vs. 28% (p = 0.001) respec-
tively). In our experiment we did not observe any differences in
fetal outcomes in animals with/with-out anti-ureaplasma IgG,
except for the presence of meconium-stained AF, which was
increased in those animals with IgG antibodies (data not
presented). Interestingly, only two fetuses developed IgG antibod-
ies in response to chronic ureaplasma infection.
It is well documented that intra-uterine infection/inflammation
is associated with adverse pregnancy outcomes (especially preterm
birth [54]), via mechanisms reviewed elsewhere [7,55,56].
Figure 6. Ureaplasmas are phase variable in vitro. Western blot analysis demonstrated that MBA expression was not affected in avirulent-
derived (E22 5.8.1) and virulent-derived (E24 3.2.1) ureaplasmas, which were serially transferred in 10B medium without the presence of polyclonal
antibodies (top panel). MBA negative escape variants were generated for both avirulent-derived and virulent-derived ureaplasma strains after serial
transfer in 10B medium containing anti-ureaplasma polyclonal antibodies (a-Up, bottom panel). P = passage number.
doi:10.1371/journal.pone.0029856.g006
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Specifically, elevation of pro-inflammatory cytokines/chemokines
such as IL-1b, Il-6, IL-8 and TNF-a within the AF and fetal
membranes have been associated with preterm delivery and
chorioamnionitis [57–62]. In this study, intra-amniotic infection
with either the avirulent-derived or virulent-derived ureaplasma
clone tended to result in the increased expression of IL-1b, IL-6
and IL-8 within chorioamnion tissue; however, there were high
levels of intra-animal variation, suggesting variability in the host
immune response. Surprisingly, we did not observe any increases
in TLR1, TLR2 or TLR6 expression, which are the pattern
recognition receptors through which the MBA activates nuclear
factor kappaB [63]. Reyes et al. [64] also noted variability in the
innate immune response after inoculation of U. parvum into the
bladder of Fischer 344 rats. They demonstrated that the severity of
urinary tract infection was associated with distinct urine cytokine
profiles. Asymptomatic urinary tract infection was associated with
elevation of interferon-c, IL-18 and monocyte chemotactic
protein-1, whereas complicated urinary tract infection with
struvite formation was characterised by increased IL-1a, IL-1b
and growth related oncogene/keratinocyte chemoattractant (anal-
ogous to human IL-8). Kasper et al. [65] also found differences in
the expression of IL-8 within human AF infected with U. parvum
and determined that bacterial load significantly influenced the
levels of AF IL-8. In our study, differences in IL-1b, IL-6 and IL-8
expression did not correlate with ureaplasma CFU/mL or gram of
tissue, or the severity of histological chorioamnionitis. Others have
demonstrated that intra-amniotic ureaplasma infection did not
result in increased levels of any tested cytokines (IL-1b, IL-1
receptor antagonist, IL-4, IL-6 and TNF-a [9]). Also, in vitro
stimulation experiments, in which human choriodecidua or fetal
membrane tissues were stimulated with ureaplasmas, demonstrat-
ed a T helper-2 dominant cytokine response (characterized by IL-
10 production, [66,67]). Taken together, these data suggest that
the host innate immune response to intra-amniotic ureaplasma
infection is not uniform, and this could account for the variety of
outcomes associated with in-utero ureaplasma infection in humans.
We found that the animals with maternal anti-ureaplasma IgG
antibodies had significantly higher levels of IL-1b, IL-6 and IL-8
within chorioamnion tissue, when compared to IgG negative
animals. We predict that a strong pro-inflammatory innate
response within the chorioamnion may have induced a humoral
immune response in these animals. This is the first time a
correlation between the innate and adaptive immune response
during intra-amniotic ureaplasma infection has been described
and is a finding unique to this animal model.
In conclusion, we have demonstrated that U. parvum avirulent-
derived and virulent-derived clones are able to chronically colonise
the AF of pregnant sheep and cause histological chorioamnionitis.
Our data suggest that ureaplasmas may not be intrinsically
virulent or avirulent; and it appears to be more likely that the host
immune response generated against intra-amniotic ureaplasma
infection is a key determinant of adverse pregnancy outcomes. Size
variation of the MBA did not correlate with different histological
outcomes, and MBA size variation occurred in all animals,
regardless of the intensity of the innate and adaptive immune
responses. This suggests that MBA size variability did not prevent
recognition by host pattern recognition receptors. However, it may
prevent the host immune response from eradicating ureaplasmas
from the amniotic cavity and thus play a role in the virulence of
these microorganisms.
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